前段时间,日本NMN临床实验的中期报告结果积极,首次临床证实了人体口服NMN后的效果,不老神药的首战告捷引发了极大的关注,站在NMN知识科普第一线,和或跃跃欲试或充满疑虑的吃瓜群众不同,小编已经开始担心自己永无退休之日啦。

 

NMN真的是抗衰老的灵丹妙药吗?它究竟“神”在哪里?关于这些疑问,小编可以从主观感受和临床实验两方面分别和大家说说NMN的具体功效。

我们先来看一看服用者的非临床反馈,距NMN产品开始在日本、美国和中国上市已有近两年,已经积累了数以万计的使用者。据服用者回馈,口服NMN后,有80%的服用者感受到身体功能明显好转,但因人而异,表现不同,包括:

 

注:服用反馈来源于网络,表中列举的每一项都有数例乃至数十例反馈,包含主观体验与体检报告,上述数据未经过系统和严格的统计处理

NMN能够改善那么多功能,似乎包治百病,这可能吗?

其实在了解了NMN的作用机理后,对它拥有如此强大的功能就不会感到奇怪了:

上一篇文中我们提到,衰老很大程度上是由人体内辅酶ⅠNAD+的缺少引起的,步入中老年后,NAD+水平急剧下降,引发各种各样的衰老症状,而NMN通过在体内迅速转化为NAD+,恢复了年轻时的水平,也恢复了正常的生理功能(调控人体数百项代谢反应、维持长寿蛋白功能、修复DNA、维持免疫系统正常功能等),从源头和根本上逆转了衰老。

如果说以上只是服用者的自身感受,小编这里还整理了一些国外文献中的实验结果,无论是单次还是长期(长达12个月),口服还是注射NMN,对各种不同模型的动物均有积极作用(按时间顺序排列)

 

 

这么多文献,这么多种功效,不知道大家有没有看花了眼?

除了提高学习能力、改善记忆力、保护视力、减少辐射损伤、提高耐力等作用外,大家最关心的应该还是NMN在改善糖尿病、心血管和神经退行性疾病方面的潜力。

这三大年龄相关疾病可以说是老年杀手,前两个就不必多说了,阿尔兹海默病和帕金森病应该是最令人害怕的老年疾病了。发病征兆弱、病理机制不明、药物治疗效果差,有多少人都不明不白地栽在了这种疾病上。

而NMN在这方面的表现可以说是可圈可点了。这些实验动物的数据结果与人体服用NMN后的反馈也是相似的,能够互相印证。

NMN在这些疾病中究竟是怎么发挥作用的?我们留到下篇为大家介绍吧。

参考文献:

Revollo, J.R., Korner, A., Mills, K.F., Satoh, A., Wang, T., Garten, A., Dasgupta, B., Sasaki, Y., Wolberger, C., Townsend, R.R., et al. (2007). Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6, 363–375.

Yoshino, J., Mills, K.F., Yoon, M.J., and Imai, S. (2011). Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14, 528–536.

Caton, P.W., Kieswich, J., Yaqoob, M.M., Holness, M.J., and Sugden, M.C. (2011). Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function. Diabetologia 54, 3083–3092.

Gomes, A.P., Price, N.L., Ling, A.J., Moslehi, J.J., Montgomery, M.K., Rajman, L., White, J.P., Teodoro, J.S., Wrann, C.D., Hubbard, B.P., et al. (2013). Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155, 1624–1638.

Peek, C.B., Affinati, A.H., Ramsey, K.M., Kuo, H.Y., Yu, W., Sena, L.A., Ilkayeva, O., Marcheva, B., Kobayashi, Y., Omura, C., et al. (2013). Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science 342, 1243417.

Karamanlidis, G., Lee, C.F., Garcia-Menendez, L., Kolwicz, S.C., Jr., Suthammarak, W., Gong, G., Sedensky, M.M., Morgan, P.G., Wang, W., and Tian, R.(2013). Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab. 18, 239–250.

Choi, S.E., Fu, T., Seok, S., Kim, D.H., Yu, E., Lee, K.W., Kang, Y., Li, X., Kemper, B., and Kemper, J.K. (2013). Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell 12, 1062–1072.

Stein, L.R., and Imai, S. (2014). Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging. EMBO J. 33, 1321–1340.

Yamamoto, T., Byun, J., Zhai, P., Ikeda, Y., Oka, S., and Sadoshima, J. (2014). Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS One 9, e98972.

Long, A.N., Owens, K., Schlappal, A.E., Kristian, T., Fishman, P.S., and Schuh, R.A. (2015). Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer’s disease-relevant murine model. BMC Neurol. 15, 19.

Yoon, M.J., Yoshida, M., Johnson, S., Takikawa, A., Usui, I., Tobe, K., Nakagawa, T., Yoshino, J., and Imai, S. (2015). SIRT1-mediated eNAMPT secretion from adipose tissue regulates hypothalamic NAD(+) and function in mice. Cell Metab. 21, 706–717.

Park, J.H., Long, A., Owens, K., and Kristian, T. (2016). Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia. Neurobiol. Dis. 95, 102–110.

de Picciotto, N.E., Gano, L.B., Johnson, L.C., Martens, C.R., Sindler, A.L., Mills, K.F., Imai, S., and Seals, D.R. (2016). Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell 15, 522–530.

Lin, J.B., Kubota, S., Ban, N., Yoshida, M., Santeford, A., Sene, A., Nakamura, R., Zapata, N., Kubota, M., Tsubota, K., et al. (2016). NAMPT-mediated NAD(+) biosynthesis is essential for vision in mice. Cell Rep. 17, 69–85.

Stromsdorfer, K.L., Yamaguchi, S., Yoon, M.J., Moseley, A.C., Franczyk, M.P., Kelly, S.C., Qi, N., Imai, S., and Yoshino, J. (2016). NAMPT-mediated NAD(+) biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. Cell Rep. 16, 1851–1860.

Lee, C.F., Chavez, J.D., Garcia-Menendez, L., Choi, Y., Roe, N.D., Chiao, Y.A., Edgar, J.S., Goo, Y.A., Goodlett, D.R., Bruce, J.E., et al. (2016). Normalization of NAD+ redox balance as a therapy for heart failure. Circulation 134, 883–894.

Wang, X., Hu, X., Yang, Y., Takata, T., and Sakurai, T. (2016). Nicotinamide mononucleotide protects against beta-amyloid oligomer-induced cognitive impairment and neuronal death. Brain Res. 1643, 1–9.

Yao, Z., Yang, W., Gao, Z., and Jia, P. (2017). Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease. Neurosci. Lett. 647, 133–140.

Wei, C.C., Kong, Y.Y., Li, G.Q., Guan, Y.F., Wang, P., and Miao, C.Y. (2017a). Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway. Sci. Rep. 7, 717.

Li, J., Bonkowski, M.S., Moniot, S., Zhang, D., Hubbard, B.P., Ling, A.J., Rajman, L.A., Qin, B., Lou, Z., Gorbunova, V., et al. (2017). A conserved NAD+ binding pocket that regulates protein-protein interactions during aging. Science 355, 1312–1317.

Wei, C.C., Kong, Y.Y., Xia, H., Li, G.Q., Zheng, S.L., Cheng, M.H., Wang, P., and Miao, C.Y. (2017b). NAD replenishment with nicotinamide mononucleotide protects blood-brain barrier integrity and attenuates delayed tPA-induced haemorrhagic transformation after cerebral ischemia. Br. J. Pharmacol. 174, 3823–3836.